New hope for advanced skin cancer: immunotherapy drug tested as first-line treatment
NCT ID NCT06981325
First seen Jan 12, 2026 · Last updated May 12, 2026 · Updated 18 times
Summary
This study tests whether the immunotherapy drug cemiplimab can shrink or control advanced basal cell carcinoma (a type of skin cancer) when used as the very first treatment. About 34 adults who have not received prior targeted therapy will receive cemiplimab, and researchers will measure how many patients respond within six months. The goal is to find a more effective option for people with advanced disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA (BCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Helios Klinikum Erfurt
RECRUITINGErfurt, Germany
-
Helios Klinikum Oberhausen
RECRUITINGOberhausen, Germany
-
Johannes Wesling Klinikum
RECRUITINGMinden, Germany
-
Nationales Centrum für Tumorerkrankungen (NCT)
RECRUITINGHeidelberg, Germany
-
Universitätsklinikum Erlangen
RECRUITINGErlangen, Germany
-
Universitätsklinikum Leipzig
RECRUITINGLeipzig, Germany
-
Universitätsklinikum Tübingen
RECRUITINGTübingen, Germany
Conditions
Explore the condition pages connected to this study.